NCT06523556 - Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Atypical Chronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative NeoplasmRecurrent Myelodysplastic/Myeloproliferative NeoplasmRecurrent Myeloproliferative NeoplasmRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic/Myeloproliferative NeoplasmRefractory Myeloproliferative Neoplasm

Interventions

BIOLOGICAL

Axatilimab

Given IV

DRUG

Azacitidine

Given IV or SC

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow biopsy and aspiration

OTHER

Survey Administration

Ancillary study

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus